Andrew Moreno

DocwireNews

The investigational drug CTO1681 is under evaluation in a phase Ib/IIa clinical trial for the prevention and management of cytokine release syndrome (CRS) in chimeric antigen receptor (CAR) T-cell therapy recipients. This trial has successfully completed its first dose, core cohort dose-limiting toxicity observation period, and is proceeding to the second cohort with its planned increased dose. CytoAgents Inc., the developer of CTO1681 and conductor of the trial, issued a press release announcing this progress.About the trial&rsquo;s results thus far, CytoAgents&rsquo; chief medical officer, Arthur P Bertolino, MD, PhD, MBA, remarked, &ldquo;[t]he safety and early efficacy data from the first dose cohort are encouraging. We look forward to evaluating the higher dose cohorts to further study the potential of CTO1681 to prevent and treat CRS, a very significant toxicity of CAR T-cell therapy.&rdquo;CTO1681 is a novel agent whose mechanism of action to counter CRS involves the patient&rsquo;s natural immune response to disease. The phase Ib/IIa trial is an open-label, rolling six-dose-escalation, multicenter study to evaluate the agent&rsquo;s safety, pharmacokinetics, and preliminary efficacy and determine its recommended phase 2 dose.The trial&rsquo;s first-dosing cohort comprised patients who underwent CAR T-cell therapy for diffuse large B-cell lymphoma. CTO1681 produced favorable safety results in this cohort, with no dose-limiting toxicities, drug-related serious adverse events, or interference with CAR T-cell therapy. Based on these data, the Safety Review Committee approved dose-escalation in the trial and proceeded to cohort 2.ReferenceCytoAgents. Press release. Businesswire. April 24, 2025. Accessed April 28, 2025. <a href="https://www.businesswire.com/news/home/20250424559289/en/CytoAgents-Announces-Completion-of-Cohort-1-Dose-escalation-Stage-of-Clinical-Phase-1B-to-Advance-Research-on-Cytokine-Release-Syndrome">https://www.businesswire.com/news/home/20250424559289/en/CytoAgents-Announces-Completion-of-Cohort-1-Dose-escalation-Stage-of-Clinical-Phase-1B-to-Advance-Research-on-Cytokine-Release-Syndrome</a>

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Trial of New Agent for CRS in CAR T-Cell Recipients Advances from Its Initial Dosing Cohort

Hematology

The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe